Document is current

Article History

Accepted: 17 September 2024

First Online: 12 November 2024

Competing interests

: Y.D. has participated in advisory boards for Clovis Oncology, AstraZeneca, Merck, Tesaro Inc (now GlaxoSmithKline), GlaxoSmithKline and Genmab. Y.D. has received research grant funding from Clovis Oncology and was involved in the preclinical and clinical development of rucaparib. Y.D. has received royalties for her involvement in the development of rucaparib. Y.D. has received research grant funding from AstraZeneca, Tesaro Inc and Roche. F.T.Z. was an employee at EMD Serono, Billerica, MA an affiliate of Merck KGaA, Darmstadt, Germany. Merck KGaA, Darmstadt, Germany, and/or its affiliates have certain rights in patents, patent applications pertaining to DNA Damage Response inhibitors, and F. Z. is named inventor on several patents. N.J.C. was involved in the development of rucaparib, receiving grant funding from Agouron Pharmaceuticals and Pfizer Oncology. She has received grant funding from BioMarin for translational studies with talazoparib. She was involved in the development of DNA-PK inhibitors and ATM inhibitors, receiving grant funding from Kudos (subsequently acquired by AstraZeneca). She was involved in the preclinical evaluation of ATR inhibitors, receiving grant funding from Vertex and Merck. She is inventor on several patents concerning PARP, DNA-PK, ATM and ATR inhibitors. She has received grant funding from Breakpoint Pharmaceuticals and has consulted for Abbvie and Tesaro on PARP inhibitors and Sierra Oncology on CHK1 inhibitors, she currently consults for Duke Street Bio. She diverts her royalty payments to charity.